Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy

PLoS One. 2021 Jul 15;16(7):e0253936. doi: 10.1371/journal.pone.0253936. eCollection 2021.

Abstract

Background: Intermediate risk prostate cancer represents a largely heterogeneous group with diverse disease extent. We sought to establish rates of adverse pathological features important for radiation planning by analyzing surgical specimens from men with intermediate risk prostate cancer who underwent immediate radical prostatectomy, and to define clinical pathologic features that may predict adverse outcomes.

Materials and methods: A total of 1552 men diagnosed with intermediate risk prostate cancer who underwent immediate radical prostatectomy between 1/1/2005 and 12/31/2015 were reviewed. Inclusion criteria included available preoperative PSA level, pathology reports of transrectal ultrasound-guided prostate biopsy, and radical prostatectomy. Incidences of various pathological adverse features were evaluated. Patient characteristics and clinical disease features were analyzed for their predictive values.

Results: Fifty percent of men with high risk features (defined as PSA >10 but <20 or biopsy primary Gleason pattern of 4) had pathological upstage to T3 or higher disease. The incidence of upgrade to Gleason score of 8 or higher and the incidence of lymph node positive disease was low. Biopsy primary Gleason pattern of 4, and PSA greater than 10 but less than 20, affected adverse pathology in addition to age and percent positive biopsy cores. Older age and increased percentage of positive cores were significant risk factors of adverse pathology.

Conclusion: Our findings underscore the importance of comprehensive staging beyond PSA level, prostate biopsy, and CT/bone scan for men with intermediate risk prostate cancer proceeding with radiation in the era of highly conformal treatment.

MeSH terms

  • Aged
  • Biopsy, Needle*
  • Humans
  • Male
  • Multivariate Analysis
  • Neoplasm Grading
  • Prostatectomy
  • Prostatic Neoplasms*
  • Risk Factors

Grants and funding

The author(s) received no specific funding for this work.